OP449, a SET antagonist reactivated PP2A and significantly reduced JAK/STAT5 and PI3K/AKT pathways in vitro CD34+ and K562 CML cells, as well as alleviated tumour burden in vivo xenografted mice with human CML cells [182,186]. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.